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S100A8 and S100A9 are both members of the S100 family and have been shown to play roles in myeloid differentiation, autophagy,
apoptosis, and chemotherapy resistance. In this study we demonstrate that the BET-bromodomain inhibitor JQ1 causes rapid
suppression of S100A8 and S100A9 mRNA and protein in a reversible manner. In addition, we show that JQ1 synergises with
daunorubicin in causing AML cell death. Daunorubicin alone causes a dose- and time-dependent increase in S100A8 and S100A9
protein levels in AML cell lines which is overcome by cotreatment with JQ1. This suggests that JQ1 synergises with daunorubicin
in causing apoptosis via suppression of S100A8 and S100A9 levels.
1. Introduction
Acute myeloid leukemia is the most common leukemia
in adults accounting for around 80% of cases [1]. It is a
clonal disorder of the myeloid lineage of white blood cells
characterised by the arrest of differentiation of immature
‘blast’ cells in the bone marrow. Diagnosis and posttreatment
monitoring of AML are generally accomplished using a
combination of karyotype analysis and reverse transcriptase
polymerase chain reaction (RT-PCR) or fluorescent in situ
hybridization (FISH) for specific abnormalities. However
around half of AML patients have a normal karyotype and
intermediate prognosis. Furthermore, with limited excep-
tions little improvement in outcome for AML patients has
been achieved with only around 35% of younger fit patients
cured of their disease. Hence, additional cellular targets need
to be identified in order to develop new chemotherapeutic
treatment strategies.
S100A8 and S100A9 are part of the 22 member calcium
binding EF-hand containing S100 superfamily of proteins
that function predominantly in the innate immune system
[2]. These low molecular weight proteins exhibit both cell
type and tissue specific expression. S100A8 and S100A9
are able to form homodimers, heterodimer, and oligomers
which can have distinct and even antagonistic functions.
Both proteins are particularly highly expressed in cells of
the myeloid lineage, particularly neutrophils where they
account for around 45% of total cytoplasmic protein. Recent
studies have highlighted S100A8 and S100A9 as having an
important role in cancer pathogenesis. High levels of both
proteins are found in cancer tissues with increased expression
appearing to be a marker of tumour aggressiveness [3]. In
AML, high levels of S100A8 [4] and S100A9 are correlated
with poor overall survival predominantly in patients with
myelomonocytic differentiation (M4, M5) [4, 5] and in de
novo pediatric AML patients [4], whilst low S100A8 and
S100A9 levels correlate with good prognosis in childhood
AML with IDH1/2 mutations [6]. Furthermore, high expres-
sion of S100A8 is associated with chemoresistance in AML
[7] whilst calprotectin (S100A8/S100A9 heterodimer) causes
glucocorticoid resistance in infant ALL [8]. S100A8 induced
chemoresistance is thought to be caused by promoting
autophagy and antiapoptotic effects [7].These studies suggest
that targeting S100A8 and S100A9 may lead to improved
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outcomes not only in treatment of AML but also for many
solid tumours. Therapies might have antimetastatic effects
and help overcome drug resistance.
Targeted inhibition of BRD4, a member of the BET-
bromodomain family of transcriptional regulators, has been
demonstrated to have therapeutic potential in AML [9].
BET-bromodomain proteins act by ‘reading’ histone acety-
lation marks, thus facilitating transcriptional activation.
Antileukemic mechanisms induced by BET inhibitors, such
as JQ1, are currently not well understood but are believed to
involve suppression of MYC.
In this study, we show that in AML cells S100A8 and
S100A9 expression is downregulated by JQ1 and upregulated
by the anthracycline daunorubicin. Furthermore we show
that JQ1 synergises with daunorubicin to cause apoptosis in
AML cell lines. We hypothesize that JQ1 stimulates apoptosis
by overcoming autophagy in an S100A8/A9-dependent man-
ner.
2. Methods
2.1. Materials. Penicillin, streptomycin, L-glutamine, dauno-
rubicin hydrochloride, Histopaque 1077, and RPMI 1640
were from Sigma (Poole, UK). TRIzol and reverse tran-
scription polymerase chain reaction (RT-PCR) primers were
purchased from Invitrogen (Paisley, UK); foetal calf serum
was from Biosera (Ringmer, UK) and WST-1 from Roche
(Welwyn Garden City, UK) 4-20% gradient gels from (Bio-
Rad). The QuantiTect reverse transcription kit was from
Qiagen (Manchester, UK) and TaqMan probes were from
Life Technologies. Antibodies against S100A8 (ab180735) and
S100A9 (ab63818) were fromAbcam (Cambridge, UK). Anti-
cleaved caspase 3 Asp 175 (#9661) was from Cell Signalling
Technology (Hitchin, UK); anti-rabbit Alexa Fluor 488 from
Life Technologies (Paisley, UK); and anti S100A8/S100A9
heterodimer from R&D systems (Abingdon, UK)
2.2. Microarray Analysis. OCI-AML3, KG1, and THP-1 cells
were treated with 0.5 𝜇M (+)-JQ1 for 16 hours in triplicate
experimental biological replicates. RNA was extracted with
the TRIzol reagent and analysed using an Agilent 2100
bioanalyzer. All RNA used had a RNA integrity number
(RIN) value of greater than 8.0. Transcriptional profiling for
control and treated cells was performed using the Illumina
expression microarrays. Raw data was normalized with a
variance stabilizing transformation followed by robust spline
normalization using the R package Lumi. Expression changes
of genes were calculated by comparing the expression levels
of treatment versus control untreated.
2.3. Leukemia Cell Lines and Patient Samples. Human
Leukemia OCI-AML3 (FAB M4) and OCI-AML2 (FAB M4)
and were kind gifts from Dr Terry Gaymes (Kings College,
London, UK) KG1 (FGFR1OP2-FGFR1 rearrangement), and
THP-1 (MLL-AF9) cells were a kind gift fromDr. LisaWood-
bine (GenomeCentre, SussexUniversity). Cells were cultured
in RPMI 1640 supplemented with 10% foetal calf serum,
2mM-glutamine, penicillin (100 IU/mL), and streptomycin
(100 𝜇g/mL). The identity of the OCI-AML3 cell line was
confirmed by carrying out a restriction-sensitive PCR assay
for mutated DNMT3A at codon R882 that this cell line
harbours [10].
A total of 18 AML patient samples were studied (Table 1).
All primary bone marrow aspirates were taken from routine
diagnostic specimens after informed consent of the patients.
The project received approval from the local ethics committee
(The Brighton Blood Disorder Study, references 09/025/CHE
and 09/H1107/1) and was conducted in accordance with the
Declaration of Helsinki. Mononuclear cells were isolated by
Histopaque 1077 density gradient purification. Peripheral
blood was taken from healthy volunteers. Monocytes and
lymphocytes were prepared from peripheral blood mononu-
clear cells by differential adhesion [11, 12]
2.4. Cell Viability Assays. For cell lines, cell viability was
assessed using a WST-1(4-[3-(4-iodophenyl)-2-(4-nitro-
phenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) assay.
20,000 cells were plated per well in 96-well plates and were
incubated in the presence of compound for the times indi-
cated. Two to four hours after the addition of WST-1, plates
were read at 450 nm in a Biotek Synergy HT plate reader
(Biotek, Potton, UK) and Gen5 version 2.04 software. The
viability of untreated cells was set as 100%, and viability in
other groups was calculated by comparing the optical density
readings with the control. All compounds were dissolved in
dimethylsulfoxide and stored at -20∘C. Dilutions in PBS were
used for experiments [12].
2.5. Immunolabelling. Cells were smeared onto poly-l-lysine
coated slides and air dried for 1 hr. Preparations were fixed
in methanol -20∘C for 5 min and then blocked in antibody
diluting solution containing 0.1% Tween 20 for 30 min.
Rabbit anti-s100A8 (1:200) s100A9 (1:200) or S100A8/S100A9
heterodimer (1:250) were applied overnight at 4∘C. After
washing through PBS, cells were incubated in anti-rabbit
Alexa Fluor 488 (1:250) for 30min. After a final wash through
PBS, the slides were incubated in DAPI (4󸀠,6-diamidino-2-
phenylindole) for 5 min and then mounted in Citifluor anti-
fade mounting medium and viewed for fluorescence using a
Leica DM 5000B microscope fitted with a Leica DPC300FX
digital camera (Leica, London, UK).
2.6. Quantitative RT-PCR. Total RNA was extracted from
cells using TRIzol reagent according to the manufacturer’s
instructions. RNA(1 𝜇g) was reverse transcribed using a
QuantiTect cDNA kit and the PCR reactions were performed
using the TaqMan Gene Expression Assays (Applied Biosys-
tems) c-MYC (Hs00811069 g1), S100A8 (Hs00374264 g1),
S100A9 (Hs00374264 g1), andGAPDH (Primer design) using
standard TaqMan reagents and protocols on a MX3500
(Stratagene) qRT-PCR machine. The ΔΔct method was used
for relative expression quantification using the average cycle
threshold for GAPDH RNA to normalize gene expression
levels between samples. All experiments were performed in
triplicate and expression levels were compared between JQ1
and (-)-JQ1-treated cells using a two-tailed t-test with P values
< 0.05 [13].
Bone Marrow Research 3
Table 1: Characteristics of primary AML samples.
BSMS number Sex Age Diagnosis Cytogenetics Gene Mutations
0131 F 75 AML Normal None detected
1007 M 58 AML Normal NPM1 mutated
1010 M 76 AML Normal None detected
1013 M 76 AML Normal None detected
1015 M 85 AML Normal None detected
1019 M 33 AML Inv16 None detected
1022 M 76 AML Normal None detected
1024 M 68 AML Normal None detected
1026 M 75 AML Normal None detected
1030 M 70 AML Normal DNMT3A, FLT3, TET, SRSF2 mutations
1031 M 60 AML Normal None detected
1032 M 52 AML Normal None detected
1033 M 72 AML Normal TET2, SRSF2, ASXL1, RUNX1 mutations
1036 M 74 AML Normal None detected
1037 M 48 AML Normal NPM1, FLT3 mutated
1038 M 74 AML Monosomy 7 None detected
1041 F 81 AML Normal None detected
1045 M 57 AML Normal FLT3 mutated
2.7. Western Immunoblotting. OCI-AML3 cells were treated
with 0.5 or 1 𝜇M JQ1 for 72 hr and then harvested. Proteins
were extracted in sample buffer containing protease inhibitor
tablets. Samples were then diluted in loading buffer (with
𝛽-mercaptoethanol), boiled for 7 min, and subjected to gel
electrophoresis on 4-20% SDS polyacrylamide gels. A total
of 50 𝜇g of cell extract was loaded per lane. Proteins were
electrophoretically transferred onto a PVDF membrane for
1 hr at 30mA constant current. Membranes were blocked
with 5% milk for 1 hr at room temperature and then rotated
overnight at 4∘C with primary antibody S100A8 (1:500),
S100A9 (1:500), and GAPDH (1:10000) in TBS 0.1% Tween.
Fluorescently linked secondary antibodies were used at a
dilution of 1:20,000 for 1 hr. Blots were analysed using a Licor
Imaging system.
3. Results
3.1. Microarray
3.1.1. S100A8 and S100A9 mRNA Are Expressed by Leukemia
Cell Lines and Patient Samples. Microarray experiments con-
ducted on leukemia cell lines treated with the bromodomain
inhibitor JQ1 showed that JQ1 causes a significant downreg-
ulation of S100A8 and S100A9 transcripts in OCI-AML3 cells
(Figure 1). Downregulation was also seen to a lesser extent
in THP-1 cells; however, these cells had lower basal levels
of both S100 genes. KG1 cells expressed extremely low levels
of S100A8 or S100A9 mRNA (not shown). Thus, we initially
conducted experiments to confirm the levels of S100A8 and
S100A9 mRNA in these cell lines and to determine S100A8
and S100A9 expression in bone marrow mononuclear cells
(BMMCs) and peripheral bloodmononuclear cells (PBMCs).
Results from qPCR experiments on cell lines (Figure 2(a))
revealed levels of transcripts varied across the cell lines with
HL60 and KG1 cells expressing very little of the mRNAs
confirming our microarray data and previous publications
[1]. Likewise, there was considerable variation in mRNA
expression across the BMMCs from 18 AML patients (Fig-
ure 2(b)). However, levels were all significantly higher than in
OCI-AML3 cells. Patient characteristics are shown in Table 1.
Monocytes prepared from healthy donors showed very high
levels of both S100 transcripts as expected serving as a positive
control (see Figure 2(b)).
3.1.2. BET-Bromodomain Inhibitor JQ1 Downregulates S100A8
and S100A9 in AML Cells and Primary Blood Cells. We next
sought to confirm the effects of JQ1 on S100A8 and S100A9
mRNA. Both cell lines andmonocytes and lymphocytes from
healthy volunteers responded to JQ1 with a robust decrease
in both S100A8 and S100A9 mRNA (Figures 3(a) and 3(b)).
qPCR confirmed that JQ1 suppresses S100A8 and S100A9
mRNA in a dose- and time-dependent manner (Figures 3(c)
and 3(d)). S100A8 mRNA was marginally more suppressed
than S100A9mRNA after JQ1 treatment in all cell lines tested.
Using OCI-AML3 cells we found that maximal suppression
occurred within 30 mins of treatment with 0.5𝜇M JQ1 and
the time frame was comparable to c-Myc downregulation
(Figure 3(d)). Suppression of these mRNAs was reversible
with S100A8 and S100A9 exceeding control levels within 24hr
of removal of JQ1 (Figure 3(e)). Western blotting showed
that JQ1 treatment caused significant downregulation of
S100A8 protein with S100A9 downregulating to amuch lesser
extent (Figure 4(a)).This was confirmed by immunolabelling
(Figure 4(b)) which revealed that S100A8 was not uniformly
expressed in the cells. Approximately 16% of cells were very
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Figure 1: Summary of S100A8 and S100A9 microarray analysis. OCI-AML3 cell lines were treated with 0.5𝜇M JQ1 for 16hr.
(a)
(b)
Figure 2: Expression of S100A8 and S100A9 mRNA in AML cell lines. qRT-PCR was used to analyse the expression of S100A8 and S100A9
mRNA in cell lines (a) and mononuclear cells from patient and healthy donors (b). Results were calculated using the ΔΔct method and
expressed relative to the housekeeping geneGAPDH.Note that in patient samples the levels of both S100A8 and S100A9mRNAare exceedingly
high compared to GAPDH.
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(a) (b)
(c) (d)
(e)
Figure 3:Regulation of S100A8andS100A9mRNAexpression byBET-bromodomain inhibition. qRT-PCRwas used to show that regulation
of S100A8 and S100A9mRNA by JQ1 in AML cell lines (a) and primary mononuclear cells (b). OCI-AML3 cells were used to show the effect
of JQ1 was (c) dose-dependent, (d) time-dependent, and (e) reversible. 0.5𝜇M JQ1 was used for time course and reversibility experiments.
Results are expressed relative to GAPDH (mean ± SEM, n=3).
brightly S100A8 positive in control experiments reducing to
5% in cells treated with JQ1 0.5𝜇M for 72 hr (Figure 4(c)).
S100A9 immunolabelling was much more homogenous
though after JQ1 treatment the appearance of the labelling
was more punctate (not shown). Immunolabelling with an
antibody that detects S100A8/A9 (calprotectin) only when
they are associated as heterodimers revealed that majority
of S100A8 and S100A9 are not in heterodimeric form with
less than 2% of cells expressing the S100A8/A9 heterodimer
(Figure 4(d)).
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(a) (b)
(c) (d)
Figure 4: Effect of JQ1 on S100A8 and S100A9 protein expression in the OCI-AML-3 cell line. Cells were treated with 0.5𝜇M for 48 hr;
then extracts were subject to Western blotting (a) or immunolabeling for S100A8 and S100A9 (b). Counts of highly S100A8 positive cells are
shown in (c) (mean ± SEM, n=3). Immunolabeling for S100A8/S100A8 heterodimer is shown in panel (d).
3.2. The Effect of JQ1 on Patient Samples. We tested 0.5𝜇M
JQ1 of S100A8 and S100A9mRNA on BMMC’s isolated from
patient samples. Unlike cell lines and cells from healthy
volunteers, JQ1 often caused an increase in S100A8 and/or
S100A9 mRNA expression (Figures 5(a)–5(c)). In some
patient samples however JQ1 suppressed expression of either
or both mRNAs (Figure 5(d)).
3.3. JQ1 Synergises with Daunorubicin in Inducing AML Cell
Death. As we have shown that JQ1 suppresses S100A8 and
S100A9 expression and S100A8 has been shown to promote
chemoresistance in leukemia cells [7], we hypothesised that
JQ1 may enhance the effects of drug action in AML cells. Cell
viability assays showed that JQ1 treatment synergised with
the anthracycline daunorubicin in causing cell death in OCI-
AML 3 cells (Figure 6(a)). This was also seen in THP-1 cells
(Figure 6(a)). Furthermore, immunolabelling for activated
caspase 3 D175 reveals a synergistic increase in apoptosis
when both drugs are used together (Figure 6(b)). Western
blotting experiments showed that daunorubicin causes a
dose- and time-dependent increase in S100A8 and S100A9
protein expression that was overcome by 0.5𝜇M JQ1 (Figures
6(c) and 6(d)). An increase was also seen inmRNA levels (not
shown).
4. Discussion
In this study we have shown that the BET-bromodomain
inhibitor JQ1 suppresses expression of S100A8 and S100A9
mRNA and protein in AML cell lines and PBMCs. This
effect is dose-dependent and reversible. S100A8 and S100A9
downregulation occurs rapidly with a time course paralleling
c-myc downregulation, a well-characterised target of BET-
bromodomain inhibitors. Application of JQ1 to primaryAML
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Figure 5: Effect of BET-bromodomain inhibition on AML patient samples. BMMCs from four patients were treated with 0.5𝜇M JQ1 for
48hr and then S100A8 and S100A9mRNA levels quantified by qRT-PCR.
cells however does not always result in S100A8 and S100A9
downregulation. Rather, in most, but not all cases, upregula-
tion of mRNA is seen. This may be because the effects of JQ1
are influenced by the mutational status of the leukemia. This
observation needs to be explored more thoroughly in a larger
cohort of patient samples. Immunolabelling experiments
suggest that S100A8 and S100A9 are largely present in AML
cells as homodimers or oligomers as an antibody specifically
detecting S100A8/S100A9 heterodimer detected very few
positive cells.
Furthermore, we show that JQ1 synergises with the
anthracycline daunorubicin in causing AML cell death and
may play a role in overcoming chemoresistance. We hypoth-
esize that JQ1 helps overcome chemoresistance by reducing
S100A8 and S100A9 levels in AML cells which in turn leads to
inhibition of autophagy.Our results support and complement
data of Yang et al., 2014, who show that overexpression of
S100A8 leads to chemoresistance in some leukemia cell lines,
one of which (HL60) is an AML cell line. This is caused
by S100A8 induction of autophagy via binding to autophagy
regulator BECLIN1 [7]. In addition, elevated S100A8 and
S100A9 cause glucocorticoid resistance in pediatric acute
lymphoblastic leukemia [8]. It has recently been reported that
JQ1 inhibits autophagy in an AML cell line bearing an NPM1
mutation (OCI-AML3 cell line used here) or an MLL fusion
by a mechanism involving NPM1 and HEXIM1 [14]. Further-
more additional support for JQ1 playing a role in autophagy
comes from the observation that, in addition to suppression
of S100A8 and S100A9, JQ1 causes MYC downregulation,
which in turn leads to impairment of autophagy [15] and our
microarray data from OCI-AML3 cells (unpublished) shows
a significant increase in the mRNA of autophagy related
genes LAMP2, SQSTM1, OPTN, and MAP1LC3B. However,
in otherAML cell lineswith leukemia stem cell like properties
(e.g., KG1 cells), JQ1 induced autophagy [16]. These cell
lines, unlike the OCI-AML3 cells, are largely resistant to JQ1
induced apoptosis [17].
Clearly, the role of JQ1 in regulating autophagy is context-
dependent, with the mutational status of the AML playing
an important role. As mentioned above, this hypothesis is
supported by our observations on patient samples. Moreover,
Sakamaki et al., 2017 [18], show that bromodomain protein
BRD4 is a repressor of autophagy in a panel of adherent
cell lines, further demonstrating the contextual role of bro-
modomain proteins. In leukemia cell lines, it is possible that
the expression of S100A8 and S100A9 determines the effect
that bromodomain inhibition has on autophagy. High level
S100A8 and S100A9 expression may predispose cells to JQ1
induced autophagy whereas cells with very low level S100A8
and S100A9 (e.g., KG1 cells)may respond to JQ1 by promoting
autophagy.
Interestingly, we found that application of daunorubicin
alone to AML cell lines results in a robust increase in
S100A8 and S100A9 levels and that this increase could be
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(a) (b)
(c) (d)
(e)
Figure 6: Effects of JQ1 and daunorubicin on S100A8 and S100A9 expression in OCI-AML3 cells. Cells were incubated in medium
containing various concentrations of daunorubicin with or without 0.5𝜇M JQ1 for 48 hr at 37∘C. After incubation cell viability (a) was
measured using WST-1 reagent and detection at 450nm or activated caspase 3 was detected by immunolabelling and caspase 3 positive cells
counted (mean ± SEM, n=3). In (a) the legend corresponds to the data lines from top to bottom (b). Western blotting of (c) OCI-AML3 cells
treated with lane 1: daunorubicin 0.5𝜇M; 2: daunorubicin 2.5𝜇M; 3: JQ1 0.5𝜇M; 4: daunorubicin 0.5𝜇M plus JQ1 0.5𝜇M; 5: control for 48hr,
and (d) time course of induction of S100A8 and S100A9 protein expression by 0.5𝜇M daunorubicin. (e) shows changes in mRNA expression
after 24 hr treatment with 0.5𝜇M daunorubicin.
overcome by JQ1. This suggests that daunorubicin induces
chemoresistance by upregulating levels of these proteins
via stimulation of autophagy. Likewise Yang et al., 2014,
reported that doxorubicin and vincristine induced S100A8
expression in leukemia cell lines and that overexpression
of S100A8 correlated with decreased sensitivity to these
drugs. Daunorubicin has been shown to induce autophagy in
leukemia cell lines by activation of the MEK/ERK pathway
[19] which in turn induces expression of S100A8 and S100A9
in cancer cells [3].
Inhibition of S100A8 and S100A9 activitymay have signif-
icant implications in cancer chemotherapy. Indeed inhibition
of S100A9 by tasquinimod, a quinoiline-3-carboxamide
derivative, throughmodulation of the tumourmicroenviron-
ment has shown promising effects in preclinical models [20].
Further studies are required to determine the effects of JQ1
on autophagy in our experiments and to confirm that S100A8
and S100A9 are necessary and sufficient to overcome these
effects. Targeting autophagy may prove to be a valuable tool
in overcoming chemoresistance in some forms of AML [21].
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